Results for pachydermatis translation from Maltese to English

ir-reżistenza ta’ malassezia pachydermatis għal azoles, li tinkludi posakonażol, ma kinitx irrappurtata.
malassezia pachydermatis resistance to azoles, including posaconazole, has not been reported.

posakonażol hu 40–100 darba iktar potenti in vitro kontra malassezia pachydermatis minn klotrimażol, mikonażol u nistatin.
posaconazole is 40 – 100 times more potent in vitro against malassezia pachydermatis than clotrimazole, miconazole and nystatin.

għall-kura ta’ otite esterna akuta u taħrix akut ta’ otite rikorrenti esterna assoċjata ma’ staphylococcus pseudintermedius u malassezia pachydermatis.
for the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with staphylococcus pseudintermedius and malassezia pachydermatis.

il-kumitat għall-prodotti mediċinali għall-użu veterinarju (cvmp) ikkonkluda li l-benefiċċji ta’ easotic huma akbar mir-riskji tiegħu għat-trattament ta’ otite esterna akuta u taħrix akut ta’ otite esterna rikorrenti fil-klieb assoċjati ma’ batterji suxxettibbli għal ġentamiċina u fungi suxxettibbli għal mikonażol b’mod partikolari l-malassezia pachydermatis u rrakkomanda li easotic jingħata awtorizzazzjoni għat-tqegħid fis-suq.
the committee for medicinal products for veterinary use (cvmp) concluded that the benefits of easotic exceed the risks for the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with bacteria susceptible to gentamicin and fungi susceptible to miconazole in particular malassezia pachydermatis, and recommended that easotic be given a marketing authorisation.